Faster diagnosis for possible lymphoma using flow cytometry
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a faster way to diagnose lymphoma using a special test called flow cytometry on a small sample from your lymph node. It aims to give results in hours instead of days, so you can start treatment sooner if needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You are having tests because you have swollen lymph nodes (lumps) that might be cancer.
- Your doctor thinks lymphoma (a type of blood cancer) is one possible cause.
- You are able to give your consent to take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a faster way to get a tissue sample from lung cancer or lymphoma tumors that are near the esophagus or stomach. The goal is to start your treatment sooner by using a special ultrasound scope to do a biopsy right away.
This trial studies how changing your immune system (with earlier treatments) affects cancer by collecting immune cells from your blood using a process called lymphapheresis. It may help researchers find better ways to monitor immune-related responses and side effects.
This study checks whether measuring a blood test called “circulating tumor DNA” (ctDNA) helps monitor childhood lymphoma during treatment. It’s meant to see if ctDNA tracking can provide useful information alongside standard exams.
This trial looks at whether PET/CT scans can better predict outcomes in people with fast-growing lymphoma. If you are newly diagnosed and receiving standard treatment, the study may help refine how response is evaluated.
This study uses advanced blood tests (flow cytometry) to find cancer cells more accurately in people with cutaneous T-cell lymphoma. It could lead to better monitoring of your condition.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.